EVR

[HoustonPops]

If I was undetected at week 4 and 12 on triple combo therapy with Incivek.  What are my chances of relapse and not achieving SVR.

[HoustonPops]

AWESOME!!!

[pooh55811]

Here is another article which says the same thing but may be easier to read:

"Results from the ADVANCE trial strongly suggested that 24 weeks of therapy is sufficient for patients with eRVR.[29] In the T12PR48 arm of this trial, patients with an eRVR received 12 weeks of triple therapy followed by 12 weeks of pegIFN/RBV, whereas patients without an eRVR received 12 weeks of triple therapy followed by 36 weeks of pegIFN/RBV. Among patients who achieved an eRVR and received 24 total weeks of therapy, the SVR rate was 89%, confirming that this strategy results in a very high SVR rate (Figure 11). The robustness of response-guided therapy was confirmed by the ILLUMINATE trial, in which treatment-naive patients with genotype 1 HCV who achieved eRVR after 12 weeks of telaprevir were randomized to receive either 12 weeks or 36 weeks of pegIFN/RBV, for a total therapy duration of 24 or 48 weeks, respectively (Capsule Summary).[30] Among patients with eRVR, 92% achieved SVR with 24 total weeks of therapy vs 88% with 48 total weeks of therapy."

http://www.clinicaloptions.com/Hepatitis/Treatment%20Updates/HCV%20New%20Agents/Module/Practical_Guide/Pages/Page%204.aspx

You may have to register for these but there is no charge.

[HoustonPops]

Thank You!!!  Things are looking up.  :)

[pooh55811]

If you look at the data below you will see that your chance for SVR is excellent because you were UND at weeks 4 and 12. From the data below, your chance for SVR ranges around 89 to 92%.

Unless there is something we do not know, or there are other factors involved, your chances are excellent.

It is possioble that you could have a viral breakthrough or you could relapse, but those possibilities are not great as you can see from the figures below.

" In ADVANCE, patients who had undetectable HCV RNA from Weeks 4 to 12, termed extended rapid virologic response (eRVR), were eligible to stop therapy at Week 24. A total of 58% ..... of patients receiving T12PR ...,  met criteria for shortened therapy. In keeping with their early initial response, these patients typically responded well to therapy, with overall SVR rates of 89% ....[Jacobson 2011a] To confirm that this response-guided therapy approach is an appropriate strategy when using telaprevir, the ILLUMINATE trial randomized patients achieving an eRVR on telaprevir, peginterferon, and ribavirin to 24 or 48 weeks of dual peginterferon/ribavirin therapy (Capsule Summary).[Sherman 2011a] Of the 540 patients enrolled in the study, 65% achieved an eRVR and entered the randomization. Subsequent SVR rates were high in both the 24- and 48-week arms (92% vs 88%, respectively), indicating that treatment can be shortened in patients who achieve an eRVR on this regimen. "

http://www.clinicaloptions.com/inPractice/Hepatology/Hepatology/ch8_Mgmt_of_Hep_C_Infection/Pages/Page%207.aspx


Best of luck.